Related Tags >> Phase III Clinical Trial Phase II adverse events

safety profile News

Most Popular safety profile Story

Insulin retreats blamed for Generex stock drop

March 11, 2008 — 6:59am ET

Generex is firmly in the camp that sees the glass as half full. After seeing its share price slide 16 percent yesterday, the developer attributed the sudden setback to decisions by Eli Lilly, Read more...

safety profile Press Releases

Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achiev
SANUWAVE’s dermaPACE Clinical Trial Results Highlighted in CME Presentation at Desert Foot Congress
Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
In the Treatment of Asthma, Merck’s Singulair Accounts for More Than a Quarter of First-Line Maintenance Therapy

Latest Headlines

Indevus shares plunge on approval delay
June 4, 2008
Insulin retreats blamed for Generex stock drop
March 11, 2008
NeurogesX pain patch fails a late-stage trial
February 28, 2008
Sirtris causes stir with positive trial data
January 8, 2008
ThromboGenics touts Phase II eye therapy results
December 4, 2007
Biovail shares sink after FDA schedules review
November 20, 2007
Theratechnologies reports positive Phase III results
October 1, 2007
Press Release: BMS Reports on First Phase II Short-Term Study of Dapagliflozin
June 25, 2007
Press Release: Roche's Phase III ACTEMRA Demonstrate Smprovement in Patients with RA
January 24, 2007
Roche drug hits endpoint in late-stage RA trial
January 23, 2007
Press Release: Panacos Pharmaceuticals Bevirimat Study Falls Short
December 20, 2006
Press Release: Theratechnologies Reports Positive Phase 3 Results for TH9507
December 19, 2006
Press Release: Theratechnologies Reports Positive Phase 3 Results For TH9507
December 19, 2006
Late-stage HIV drug trial delivers positive data
December 18, 2006
Press Release: Pozen Expects to Submit Revised Response to Trexima Approvable Letter by Year End
December 12, 2006
Press Release: Vanda Pharmaceuticals Confirms Iloperidone Efficacy With Positive Phase III Results
December 6, 2006
Kalypsys reaps $100 million in third round
November 28, 2006
FDA rejects Replidyne's antibiotic
October 22, 2006
Diabetes prevention spurs development programs
October 12, 2006
Cardiome upbeat on mid-stage heart drug data
September 12, 2006

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events